eRAM
encyclopedia of Rare Disease Annotation for Precision Medicine
| Disease | cystoid macular dystrophy |
| Symptom | |retinal vein occlusion |
| Sentences | 122 |
| PubMedID- 24967199 | Aqueous levels of erythropoietin in acute retinal vein occlusion with macular edema. |
| PubMedID- 19967679 | Purpose: aqueous levels of vascular endothelial growth factor (vegf) and interleukin-6 (il-6) are associated with the severity of macular edema in patients with central retinal vein occlusion (crvo). |
| PubMedID- 23690676 | Unilateral macular edema with central retinal vein occlusion in systemic lupus erythematosus: a case report. |
| PubMedID- 20801424 | Intravitreal injection of autologous plasmin enzyme for macular edema associated with branch retinal vein occlusion. |
| PubMedID- 23972086 | Aqueous soluble vascular endothelial growth factor receptor-2 in macular edema with branch retinal vein occlusion. |
| PubMedID- 21211297 | Objective: to study the correlation of visual acuity and photoreceptor in eyes with persistent cystoid macular edema associated with branch retinal vein occlusion (brvo). |
| PubMedID- 21478810 | Conclusion: these results suggest that a rebound of macular edema in eyes with branch retinal vein occlusion was more likely to occur when the intravitreal bevacizumab therapy is initiated before the macular edema reaches the maximum level. |
| PubMedID- 22044337 | Rapid resolution of macular edema associated with central retinal vein occlusion using ranibizumab after failure with multiple bevacizumab injections. |
| PubMedID- 21866074 | Methods: the subjects were 44 branch retinal vein occlusion patients with macular edema and 16 controls. |
| PubMedID- 25705695 | To compare the efficacy of different therapies in the treatment of macular edema associated with retinal vein occlusion (rvo). |
| PubMedID- 24068204 | The mechanisms responsible for macular edema with branch retinal vein occlusion (brvo) remain to be elucidated. |
| PubMedID- 24205253 | The geneva (global evaluation of implantable dexamethasone in retinal vein occlusion with macular edema) study evaluated the safety and efficacy of an intravitreal dexamethasone implant 0.7 mg versus an implant 0.35 mg versus sham injection in both brvo and crvo. |
| PubMedID- 22988344 | Ozurdex received fda approval in june 2009 for the treatment of macular edema associated with retinal vein occlusion, and in september 2010, it became the second fda-approved therapeutic agent for the treatment of noninfectious posterior uveitis.in a 26-week, multicenter, double-masked, randomized clinical study in which 229 patients were randomized in a 1 : 1 : 1 ratio receiving 0.70 mg ozurdex (n = 77), 0.35 mg ozurdex (n = 76), or sham injection (n = 76). |
| PubMedID- 26305536 | Purpose: to investigate regional changes in choroidal thickness in branch retinal vein occlusion (brvo) patients with macular edema. |
| PubMedID- 21598607 | Medium-term effects of intravitreal bevacizumab for macular edema associated with central retinal vein occlusion. |
| PubMedID- 20417567 | Objective: to evaluate the safety and efficacy of dexamethasone intravitreal implant (dex implant; ozurdex, allergan, inc., irvine, ca) compared with sham in eyes with vision loss due to macular edema (me) associated with branch retinal vein occlusion (brvo) or central retinal vein occlusion (crvo). |
| PubMedID- 20103055 | Results: eyes with macular edema associated with retinal vein occlusion typically showed foveal cystoid spaces and marked retinal swelling, especially in the outer retina. |
| PubMedID- 22876931 | Background: the influence of serous retinal detachment (srd) on visual acuity, macular sensitivity, and macular thickness is unclear after intravitreal injection of triamcinolone acetonide (ivta) for macular edema with branch retinal vein occlusion (brvo). |
| PubMedID- 21468337 | Scott et al23 demonstrated that the correlation between oct-measured center point thickness, and visual acuity letter score was statistically significant, but this relationship was, at best, modest in patients with macular edema associated with retinal vein occlusions. |
| PubMedID- 22606470 | We report our unusual experience while treating a case of hemicentral retinal vein occlusion with macular edema. |
| PubMedID- 24847256 | We report a 19-year-old patient who developed a central retinal vein occlusion (crvo) with significant macular edema and visual impairment following intense exercise and dehydration. |
| PubMedID- 24531560 | Association of electroretinogram and morphological findings in central retinal vein occlusion with macular edema. |
| PubMedID- 21805173 | Association of electroretinogram and morphological findings in branch retinal vein occlusion with macular edema. |
| PubMedID- 25336905 | Direct photocoagulation to leakage points to treat chronic macular edema associated with branch retinal vein occlusion: a pilot study. |
| PubMedID- 20935688 | Visual improvement in established central retinal vein occlusion with long-standing macular edema following systemic eculizumab treatment. |
| PubMedID- 25390716 | Conclusion: ozurdex may be effective in reducing macular edema because of a branch retinal vein occlusion in eyes refractory to multiple other treatments. |
| PubMedID- 21386915 | Visual prognosis and vitreous molecules after vitrectomy for macular edema with branch retinal vein occlusion. |
| PubMedID- 22492175 | Methods: we studied the relationship between foveal sensitivity, obtained as the "foveal threshold" by use of humphrey perimetry, and best-corrected visual acuity, converted to the logarithm of the minimum angle of resolution (logmar), for 117 eyes with epiretinal membrane (erm), 197 eyes with retinal vein occlusion associated with macular edema (rvome), and 158 eyes with central serous chorioretinopathy (csc). |
| PubMedID- 22474425 | The dexamethasone drug delivery system (dds) ozurdex, allergan, irvine, california is a biodegradable, sustained-release device approved by the us fda for the treatment of macular edema associated with retinal vein occlusion and noninfectious posterior segment uveitis. |
| PubMedID- 21191716 | Purpose: to study prognostic factors for visual acuity (va) after intravitreal bevacizumab injection (ivb) for macular edema (me) associated with retinal vein occlusion (rvo), by evaluating the correlation between the final va and va at baseline and at 1, 3, and 6 months after the initial ivb. |
| PubMedID- 21734622 | Measurement of retinal sensitivity may be useful for assessing branch retinal vein occlusion patients with macular edema. |
| PubMedID- 22553416 | The formation of lmh has been described in patients with diabetic cystoid edema and in chronic cystoid macular edema associated with retinal vein occlusion. |
| PubMedID- 23598674 | Twelve-month experience with ozurdex for the treatment of macular edema associated with retinal vein occlusion. |
| PubMedID- 26428221 | Purpose: current treatment paradigms for macular edema associated with retinal vein occlusions (rvo) often involve initial treatment with anti-vascular endothelial growth factor (vegf) agents, then switching to intravitreal dexamethasone implant (idi; ozurdex, allergan, parsippany, nj) for poor responders. |
| PubMedID- 21845030 | Grid photocoagulation combined with intravitreal bevacizumab for recurrent macular edema associated with retinal vein occlusion. |
| PubMedID- 26383643 | Recurrence of macular edema in eyes with branch retinal vein occlusion changes the diameter of unaffected retinal vessels. |
| PubMedID- 20738886 | Background: this study investigated whether soluble intercellular adhesion molecule-1 (sicam-1) has a role in the pathogenesis of macular edema associated with branch retinal vein occlusion (brvo) together with vascular endothelial growth factor (vegf). |
| PubMedID- 21337043 | Sham treatment in acute branch retinal vein occlusion with macular edema: results at 3 months (report 1). |
| PubMedID- 24325604 | Aqueous flare and inflammatory factors in macular edema with central retinal vein occlusion: a case series. |
| PubMedID- 24311895 | Ranibizumab is now fda approved for the treatment of age-related macular degeneration as well as macular edema associated with retinal vein occlusion. |
| PubMedID- 26454243 | Purpose: to determine the ability of optical coherence tomography (oct) angiography to image the microvascular structures compared with fluorescein angiography (fa) in patients with macular edema associated with branch retinal vein occlusion (brvo). |
| PubMedID- 20714746 | Background: we investigated whether pigment epithelium-derived factor (pedf) or vascular endothelial growth factor (vegf) influence macular edema in patients with branch retinal vein occlusion (brvo). |
| PubMedID- 20689798 | It is the occurrence of macular edema in retinal vein occlusion that most frequently leads to visual loss. |
| PubMedID- 21784203 | Intravitreal injection of autologous plasmin enzyme for macular edema associated with branch retinal vein occlusion. |
| PubMedID- 25411827 | Purpose: dexamethasone intravitreal implant (dex implant, ozurdex((r)); allergan, inc.) is used to treat noninfectious posterior uveitis and macular edema associated with retinal vein occlusion and diabetic retinopathy. |
| PubMedID- 21500185 | Results: nine eyes of 9 consecutive patients treated with a total of 9 sustained-release dexamethasone 0.7 mg intravitreal implants for macular edema associated with retinal vein occlusion were included. |
| PubMedID- 20531142 | Conclusion: individualized repeated intravitreal injections of ranibizumab showed promising short-term results in visual acuity improvement and decrease in cft in patients with macular edema associated with branch retinal vein occlusion. |
| PubMedID- 22358585 | Purpose: to evaluate the visual outcomes of three different treatments for macular edema associated with a branch retinal vein occlusion. |
| PubMedID- 23046435 | Changes of inflammatory factors after intravitreal triamcinolone acetonide for macular edema with central retinal vein occlusion. |
| PubMedID- 22153634 | Recurrence of macular edema in retinal vein occlusions after treatment with intravitreal ranibizumab (lucentis). |